Whalesbook
Lupin Ltd has announced record results for fiscal year 2026, achieving Rs 27,958 crores in revenue and a 29.7% EBITDA margin for the year. The company's strong performance was propelled by significant growth in its U.S. market operations. Looking ahead to fiscal year 2027, Lupin anticipates a moderation in EBITDA margins to around 25%, citing anticipated competition and rising operational costs.
Record FY2026 Performance
The pharmaceutical company posted a robust fiscal year 2026 with total revenues reaching Rs 27,958 crores. Its U.S. business segment was a key driver, generating USD 1.3 billion in sales, a notable 40% increase year-over-year, supported by strong sales of products including Tolvaptan, Mirabegron, and Risperdal Consta. In India, Lupin's core prescription business expanded by 14.5% in the fourth quarter of FY2026, outperforming the broader Indian Pharmaceutical Market (IPM) growth of 11.6% during the same period. Operationally, the company reported strong gross margins of 75% in Q4 FY2026 and improved its working capital cycle to 87 days, down from 110 days previously. Additionally, Lupin received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the U.S. Food and Drug Administration (USFDA) for its Goa manufacturing facility.
FY2027 Margin Forecast and Industry Pressures
For fiscal year 2027, Lupin management forecasts EBITDA margins to moderate to approximately 25%. This projected decrease from the current year's peak is attributed to several factors. Increased generic competition is expected, particularly in the Tolvaptan and Mirabegron markets. The company is also facing elevated logistics costs, with ocean freight rates up 15% and air freight rates up 60% due to geopolitical conditions. The patent expiry for Tolvaptan around September is also anticipated to bring additional competitors into the market.
Strategic Growth Initiatives
Lupin's strategic expansion efforts include the acquisition of Italy-based VISUfarma in July 2023. This move has significantly boosted its presence in key European markets like Italy and Spain, while simultaneously enhancing its ophthalmology product portfolio. The company is also focused on launching new products, such as Ravicti, Pegfilgrastim, and Semaglutide, which are expected to contribute to future revenue growth.
Operational and Supply Chain Challenges
The company is encountering challenges in scaling up manufacturing at contract manufacturing organizations (CMOs). These production constraints are impacting Lupin's ability to fully meet market demand for certain products, including Risperdal Consta.
Peer Landscape
Lupin operates in a competitive environment alongside other major pharmaceutical firms. Sun Pharma also holds a strong position in U.S. generics but benefits from a more diversified specialty drug portfolio. Dr. Reddy's Laboratories is similarly engaged in U.S. generics and biosimilars, with ongoing investment in R&D and complex product development. Cipla faces comparable U.S. market dynamics and is also expanding its specialty segment while managing generic competition.
What Investors Are Watching
Investors will be closely monitoring Lupin's performance against its FY2027 revenue growth and EBITDA margin guidance. Key developments to track include the market reception of new product launches, the competitive landscape following Tolvaptan's patent expiry, and the successful integration of the VISUfarma acquisition into its European operations. Management's efforts to resolve manufacturing and supply chain bottlenecks for key products and any further updates regarding U.S. facility compliance will also be under scrutiny.